[go: up one dir, main page]

AR076153A1 - Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones - Google Patents

Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones

Info

Publication number
AR076153A1
AR076153A1 ARP100100980A ARP100100980A AR076153A1 AR 076153 A1 AR076153 A1 AR 076153A1 AR P100100980 A ARP100100980 A AR P100100980A AR P100100980 A ARP100100980 A AR P100100980A AR 076153 A1 AR076153 A1 AR 076153A1
Authority
AR
Argentina
Prior art keywords
nicotine
dosage form
component
intra
oral dosage
Prior art date
Application number
ARP100100980A
Other languages
English (en)
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of AR076153A1 publication Critical patent/AR076153A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/32—Cocoa products, e.g. chocolate; Substitutes therefor characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma de dosificacion intra oral de porciones multiples que comprende al menos un agente farmacéuticamente activo o que promueve la salud, en donde al menos una porcion comprende un componente para la creacion de una sensacion organoléptica evidente. Uso de marcadores o senales sensoriales como ayuda conceptual para el sujeto que utilice la forma de dosificacion, por medio del cual la(s) sensacion(es) organolépticas es (son) tales que facilita(n) identificar al sujeto las diferentes porciones y diferenciarlas. Método y un sistema para administrar agentes activos, como nicotina y/o sus metabolitos, tales como por ejemplo cotinina, N' oxido de nicotina, nornicotina, (S) -nicotina-N-Beta-glucuronido y sus mezclas, isomeros, sales y complejos de inclusion, así como también el uso y la produccion de dichas formas de dosificacion. Reivindicacion 9: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones precedentes, donde las porciones además tienen diferente disolucion y diferentes tiempos de disolucion. Reivindicacion 10: Una forma de dosificacion intra oral de multiples porciones de acuerdo con la reivindicacion 9, donde al menos una porcion se desintegra más rápidamente que al menos otra, y donde cada porcion comprende por lo menos un ítem seleccionado de entre un componente para tratar la dependencia del tabaco, un componente farmacéuticamente activo, un componente que simula a la nicotina, un componente amortiguador de pH, un componente regulador de pH, un sabor, un componente barrera, un componente color, un componente adhesivo, un agente enmascarador de sabor, un agente blanqueador de dientes, un agente para refrescar el aliento, un agente para promover la salud oral, y un agente anticaries. Reivindicacion 23: Una forma de dosificacion intra oral de multiples porciones de acuerdo con la reivindicacion 21, donde el complejo de inclusion de nicotina es un complejo de ciclodextrina, donde la ciclodextrina usada se elige de entre las ciclodextrinas alpha-, beta e y-, derivados hidroxipropilo de ciclodextrinas alpha-, beta- e y-, ciclodextrinas sulfobutiléter, tales como por ejemplo beta-ciclodextrina sulfobutiléter, ciclodextrinas alquilatadas, tales como beta-ciclodextrina metilatada al azar, y ciclodextrinas ramificadas, tales como glucosil- y maltosil-beta-ciclodextrina. Reivindicacion 27: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones precedentes, que comprende un componente para tratar la dependencia del tabaco seleccionado de entre uno o más de vareniclina, bupropion, nortriptilina, doxepina, fluoxetina, imipramin, moclobemida, conotoxinMll, epibatidina, A-85380, lobelina, anabasina, SIB-1508Y, SIB-1553A, ABT-418, ABT-594, ABT-894, TC-2403, TC-2559, RJR-2403, SSR180711, GTS-21, y/o citisina. Reivindicacion 49: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones 9 - 27 y 32 - 47, en donde al menos una porcion de rápida disolucion comprende al menos un agente farmacéuticamente activo seleccionado de entre el grupo que consiste en fenilefrina, dextrometorfan, difenhidramina, ambroxol, clorfeniramina, canabidiol, delta-9-tetrahidrocanabinol, clofedianol, y pseudoefedrina, y donde al menos una porcion de disolucion lenta comprende al menos un agente farmacéuticamente activo seleccionado de entre el grupo que consiste en mentol, nicotina, diclonina, benzocaína, timol, salicilato de metilo y eucalipto. Reivindicacion 51: Una forma de dosificacion intra oral de multiples porciones de acuerdo con cualquiera de las reivindicaciones 9 - 27 y 32 - 50 donde al menos una porcion de disolucion rápida es una porcion comprimida y donde al menos una porcion de disolucion lenta tiene una matriz que es un cristal de caramelo duro. Reivindicacion 55: Una formulacion de acuerdo con cualquiera de las reivindicaciones 1 - 27 y 32 - 51 que comprende nicotina y/o sus metabolitos, tales como por ejemplo cotinina, N' oxido de nicotina, nornicotina, (S) -nicotina-N-beta-glucuronido y sus mezclas, isomeros, sales y complejos, en cualquier forma, para ser empleados en terapia, en donde la terapia es el tratamiento de una enfermedad seleccionada de entre el grupo que consiste en dependencia del tabaco o de la nicotina, enfermedad de Alzheimer, mal de Crohn, enfermedad de Parkinson, síndrome de Tourette, colitis ulcerosa y control de peso posterior a haber dejado de fumar.
ARP100100980A 2009-03-27 2010-03-26 Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones AR076153A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0900397 2009-03-27
US12/430,238 US20100247586A1 (en) 2009-03-27 2009-04-27 Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties

Publications (1)

Publication Number Publication Date
AR076153A1 true AR076153A1 (es) 2011-05-18

Family

ID=42791088

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100980A AR076153A1 (es) 2009-03-27 2010-03-26 Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones

Country Status (11)

Country Link
US (1) US20100247586A1 (es)
JP (1) JP2010229131A (es)
KR (1) KR20100108307A (es)
AR (1) AR076153A1 (es)
AU (1) AU2010201229A1 (es)
BR (1) BRPI1001980A2 (es)
CA (1) CA2697867A1 (es)
MX (1) MX2010003550A (es)
NZ (2) NZ598993A (es)
RU (1) RU2490010C2 (es)
ZA (1) ZA201002188B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037508T2 (hu) * 2003-07-24 2018-09-28 Glaxosmithkline Llc Szájban oldódó filmek
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
SMT201700578T1 (it) 2009-11-20 2018-01-11 Tonix Pharma Holdings Ltd Metodo e composizioni per trattare i sintomi associati al disturbo da stress post-traumatico usando ciclobenzaprina
US20110319389A1 (en) 2010-06-24 2011-12-29 Tonix Pharmaceuticals, Inc. Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
US9155321B2 (en) * 2010-08-11 2015-10-13 R.J. Reynolds Tobacco Company Meltable smokeless tobacco composition
US11116237B2 (en) 2010-08-11 2021-09-14 R.J. Reynolds Tobacco Company Meltable smokeless tobacco composition
US10206765B2 (en) 2011-01-24 2019-02-19 Leonard G. Lorch Dental floss
US9277977B2 (en) 2011-01-24 2016-03-08 Leonard G. Lorch Dental floss
US9277976B2 (en) 2011-01-24 2016-03-08 Leonard G. Lorch Dental floss
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) * 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
EP2765989B1 (en) * 2011-10-13 2016-04-13 Jaleva Pharmaceuticals LLC Methods and compositions for rapid transbuccal delivery of active agents
US9907748B2 (en) * 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) * 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
HUE060175T2 (hu) * 2012-06-15 2023-02-28 Tonix Pharma Holdings Ltd Transzmukózális felszívódásra szolgáló készítmények és módszerek
WO2014027980A1 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Oral film formulations comprising dapoxetine and tadalafil
RS65500B1 (sr) 2013-03-15 2024-06-28 Tonix Pharma Holdings Ltd Eutektičke formulacije ciklobenzaprin hidrohlorida i manitola
US10130120B2 (en) * 2013-03-15 2018-11-20 Altria Client Services Llc Use of pectin or other anionic polymers in the stabilization and controlled release of nicotine in oral sensorial tobacco products or nicotine containing non-tobacco oral sensorial products
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
US11503853B2 (en) * 2013-09-09 2022-11-22 R.J. Reynolds Tobacco Company Smokeless tobacco composition incorporating a botanical material
MY186047A (en) 2014-09-18 2021-06-17 Tonix Pharma Holdings Ltd Eutectic formulations of cyclobenzaprine hydrochloride
KR101695071B1 (ko) * 2014-12-26 2017-01-11 연세대학교 산학협력단 액상으로 약물을 분산시킨 필름형태의 약제학적 조성물
EP3273948B1 (en) 2015-03-26 2020-02-12 Patheon Softgels Inc. Liquisoft capsules
FR3034991A1 (fr) * 2015-04-17 2016-10-21 Bertin Pharma Comprime pharmaceutique bicouche, procede de fabrication et utilisation comme medicament
WO2016196878A1 (en) 2015-06-04 2016-12-08 Altria Client Services Llc Acyl nornicotines reduce sensory irritation in tobacco and nicotine products
US10016471B2 (en) 2015-06-29 2018-07-10 Phloronol, Inc. Solid pharmaceutical compositions of brown algae
JP2019501207A (ja) * 2016-01-08 2019-01-17 シーティーシー バイオ，インコーポレイテッド バレニクリンまたはこの薬学的に許容可能な塩を含有する、味の遮蔽された口腔投与用薬学製剤
ES2814296T3 (es) 2016-04-21 2021-03-26 Fertin Pharma As Producto para administración de nicotina, usos relacionados y formas de dosificación oral y métodos de producción
WO2017189375A1 (en) * 2016-04-27 2017-11-02 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and nicotine
US10653639B2 (en) 2016-05-16 2020-05-19 Cv Sciences, Inc. Pharmaceutical formulations containing cannabidiol and nicotine for treating smokeless tobacco addiction
WO2018071547A1 (en) * 2016-10-11 2018-04-19 Aucta Pharmaceuticals Powder for oral suspension containing lamotrigine
WO2018160043A1 (ko) * 2017-03-03 2018-09-07 주식회사 씨티씨바이오 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제
JP2021505629A (ja) 2017-12-11 2021-02-18 トニックス ファーマ ホールディングス リミテッド 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
RU2677125C1 (ru) * 2018-04-19 2019-01-15 Александр Александрович Кролевец Способ получения мармелада с наноструктурированным L-аргинином
EP3598968A1 (en) * 2018-07-23 2020-01-29 Adamed Pharma S.A. Solid pharmaceutical cytisine composition
GB201815420D0 (en) * 2018-09-21 2018-11-07 Cosmetic Warriors Ltd Composition
US11672862B2 (en) 2019-12-09 2023-06-13 Nicoventures Trading Limited Oral products with reduced irritation
AU2021207268A1 (en) * 2020-01-15 2022-09-08 Mcneil Ab Lozenge
AU2021289162A1 (en) * 2020-06-08 2023-02-09 Nicoventures Trading Limited Effervescent oral composition comprising an active ingredient
US12161755B2 (en) * 2020-11-14 2024-12-10 Regents Of The University Of Minnesota Sustained release device for treatment of Parkinson's disease and other disorders
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220354785A1 (en) * 2021-04-22 2022-11-10 Nicoventures Trading Limited Oral lozenge products
EP4326098A1 (en) * 2021-04-22 2024-02-28 Nicoventures Trading Limited Effervescent oral composition
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
CN114088843B (zh) * 2021-11-26 2024-01-30 上海皓鸿生物医药科技有限公司 一种伐伦克林中间体中亚硝胺类基因毒性杂质的检测方法
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US352466A (en) * 1886-11-09 Geoege cheistopheb huttemeyee
US2253800A (en) * 1936-01-03 1941-08-26 Myers Medicinal lozenge and process of froducing the same
US2311923A (en) * 1939-06-08 1943-02-23 Iodent Chemical Company Cough drop
US3877468A (en) * 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3901248A (en) * 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
US4372942A (en) * 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
US4513012A (en) * 1983-05-13 1985-04-23 Warner-Lambert Company Powdered center-filled chewing gum compositions
GB8615676D0 (en) * 1986-06-26 1986-07-30 Stoppers Co Ltd Nicotine containing lozenge
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
US4789546A (en) * 1987-02-19 1988-12-06 Consumer Products Corp. Multiple-layer tablet with contrasting organoleptic characteristics
US5236713A (en) * 1987-10-21 1993-08-17 Teikoku Seiyaku Kabushiki Kaisha Preparation for intermittently releasing active agent applicable to oral cavity
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
EP0437098A3 (en) * 1990-01-11 1991-09-18 Warner-Lambert Company Compressed confectionery tablets with at least two phases and sequential flavour delivery system
US5075114A (en) * 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
US5196436A (en) * 1990-10-31 1993-03-23 The Procter & Gamble Company Dextromethorphan antitussive compositions
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
JPH08509725A (ja) * 1993-04-30 1996-10-15 ザ、プロクター、エンド、ギャンブル、カンパニー コートされた医薬組成物
IT1264696B1 (it) * 1993-07-09 1996-10-04 Applied Pharma Res Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
US5626896A (en) * 1994-12-09 1997-05-06 A.E. Staley Manufacturing Co. Method for making liquid-centered jelly candies
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking
US5578336A (en) * 1995-06-07 1996-11-26 Monte; Woodrow C. Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making
US5776957A (en) * 1996-11-15 1998-07-07 The University Of Kentucky Research Foundation Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
GB9707977D0 (en) * 1997-04-21 1997-06-11 Procter & Gamble Centre filled confectionery
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US6583160B2 (en) * 1999-04-14 2003-06-24 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
US20010016593A1 (en) * 1999-04-14 2001-08-23 Wilhelmsen Paul C. Element giving rapid release of nicotine for transmucosal administration
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
DE19927688A1 (de) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US6491540B1 (en) * 1999-09-20 2002-12-10 Jack Barreca Center-filled supplement gum
GB0002305D0 (en) * 2000-02-01 2000-03-22 Phoqus Limited Power material for electrostatic application
WO2001089476A1 (en) * 2000-05-19 2001-11-29 Npd Llc Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
US6814978B2 (en) * 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US20020086054A1 (en) * 2001-01-02 2002-07-04 Jiajiu Shaw Controlled release system that needs no drilling
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20030077362A1 (en) * 2001-10-23 2003-04-24 Panhorst Dorothy A. Encapsulated flavors as inclusion in candy confections
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
GB0204772D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Pharmaceutical dosage forms
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
EP1449525A1 (en) * 2003-02-20 2004-08-25 Cross Chem Llc chewing gum in the form of multi-layer tablets
WO2006063189A2 (en) * 2004-12-10 2006-06-15 Novartis Ag Multi-layered chewing gum tablet with quick disintegration layer
JP2006232675A (ja) * 2005-02-22 2006-09-07 Kowa Co 複合型口腔内溶解用固形製剤
US20070092553A1 (en) * 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form

Also Published As

Publication number Publication date
NZ598993A (en) 2014-02-28
JP2010229131A (ja) 2010-10-14
NZ584267A (en) 2012-04-27
CA2697867A1 (en) 2010-09-27
RU2490010C2 (ru) 2013-08-20
AU2010201229A1 (en) 2010-11-11
ZA201002188B (en) 2011-12-28
RU2010111715A (ru) 2011-10-10
BRPI1001980A2 (pt) 2011-07-26
MX2010003550A (es) 2010-10-05
KR20100108307A (ko) 2010-10-06
US20100247586A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
CN101829036B (zh) 口腔喷雾剂
JP2019131596A5 (es)
AR060932A1 (es) Producto y su uso y elaboracion
WO2014093127A3 (en) Method of administering nicotine, thc, tobacco, cannabidiol or base alkaloid and absorption conditioning unit
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
AR058133A1 (es) Metodo de tratamiento y/o prevencion de infecciones en bebes nacidos por cesarea
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
CO6341514A2 (es) Método para reducir la variabilidad de la absorción de paracetamol en pacientes con dismotilidad gástrica
CO6491061A2 (es) Formulacion de omeprazol farmaceutica estable para administracion oral
AR066586A1 (es) Formulacion farmaceutica liquida para proveer nicotina, su uso y fabricacion
WO2008051527A3 (en) Sustained release of agents for localized pain management
Welliver New drug sugammadex: a selective relaxant binding agent.
AR042598A1 (es) Composiciones de acetaminofeno
MX2020003697A (es) Formulaciones farmaceuticas que comprenden un agonista del receptor opioide como ingredientes activos, metodos de fabricacion y usos terapeuticos de las mismas.
BRPI0900491A8 (pt) nova espuma comestível em aerosol
Rukewe et al. Spinal anesthesia in children: no longer an anathema!
AR065301A1 (es) Formulaciones farmaceuticas solidas de una dispersion homogenea de principios activos cuya solubilidad es dependiente del ph
BR112018072183A2 (pt) composição farmacêutica, e, método para prevenir uma doença de pele
Jin et al. Therapeutic Effect of Oral Itraconazole for Verruca Plana
MX2025001924A (es) Precursores de fenetilaminas y catinonas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal